Granules India’s arm gets USFDA’s nod for Vigabatrin for Oral Solution

27 Apr 2020 Evaluate

Granules India’s wholly owned foreign subsidiary -- Granules Pharmaceuticals Inc (GPI) has received approval for its Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (US FDA) for Vigabatrin for Oral Solution USP, 500 mg. It is bioequivalent to the reference listed drug product (RLD), Sabril (vigabatrin) for Oral Solution, 500 mg, of Lundbeck Pharmaceuticals LLC.

Vigabatrin for Oral Solution (brand and generic) products had U.S. sales of approximately $255 million MAT for the most recent twelve months ending in February 2020 according to IQVIA Health. Granules now has a total of 27 ANDA approvals from US FDA (25 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

605.90 -2.90 (-0.48%)
09-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1826.10
Dr. Reddys Lab 1371.60
Cipla 1488.15
Lupin 2251.80
Zydus Lifesciences 1009.40
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.